Evidence brief · printable

Hepatitis C evidence brief

One page, every section sourced. Print it or bring it on your phone.

Print or save as PDF Fits on one A4 or Letter page.

Hepatitis C: evidence brief

Open Source Medicine Foundation · page built 16 November 2026 · trial data searched 2026-11-16 · https://research.opensourcemed.info/briefs/hepatitis-c.html

Research information, not medical advice. Prepared to support a conversation with a clinician, not to choose a treatment.

Live version

Medicines with registered trials

Scale: trials listed for each medicine on the tracker's condition page, a snapshot of ClinicalTrials.gov. A trial means it is being studied, not that it works.

  • Ribavirin 8 trials
  • Peginterferon alfa-2b (SCH 54031) 5 trials
  • Daclatasvir (BMS-790052) 3 trials
  • Danoprevir 3 trials
  • Pegylated interferon alpha 2a and ribavirin 3 trials
  • BI 201335 NA 120 mg capsule 2 trials

Non-drug approaches tested

Scale: trial status on ClinicalTrials.gov (completed, results posted). Status is not a result.

  • Education, coaching and self-management 35 trials · 23 completed · 13 with results
  • Care coordination, navigation and outreach 16 trials · 10 completed · 4 with results
  • Behavioural treatment for alcohol, smoking and drug use 5 trials · 5 completed · 3 with results
  • Psychotherapy, counselling and peer support 11 trials · 10 completed · 1 with results
  • Cognitive behavioural and related therapies 4 trials · 3 completed · 0 with results
  • Nutrition counselling and food-based products 3 trials · 3 completed · 0 with results

Natural products (RepurpOS Moderate tier)

Scale: RepurpOS evidence tier, from linked trials and literature. Product quality and dose vary.

  • Silymarin
  • Black Seed Oil
  • Tudca

Biomarkers reported

Direction in patients compared with the stated comparison group, as reported in the cited study.

  • Alpha-Fetoprotein higher · Nakao et al. 2013
  • ALT higher · Woo et al. 2024
  • AST higher · Al-Rawaf et al. 2024
  • Cryoglobulins higher · Siagris et al. 2002
  • FIB-4 Index higher · Krassenburg et al. 2023
  • Gamma-Glutamyl Transferase (GGT) higher · Khadem Ansari et al. 2015

Trials recruiting

Status as recorded on ClinicalTrials.gov when searched (2026-11-16); check the registry for current status and eligibility.

  • Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia,… NCT06159504
  • Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in… NCT07040319
  • Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir… NCT03855917
  • Enhancing Uptake of Needle and Syringe Programs in Canadian Federal Prisons NCT07122219
  • Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who… NCT06179498
  • Project I Test: Implementing HIV Testing in Opioid Treatment Programs NCT03135886

What we don't know yet

Gaps in registered trials, from the evidence-gap map. A gap is not a recommendation.

  • Among 21 trials of supplements and nutraceuticals found, none measured symptom severity and disease activity 12 trials of other approaches did
  • Among 35 trials of cognitive training and education found, none measured quality of life 5 trials of other approaches did
  • Among 16 trials of care delivery and health services found, none measured quality of life 5 trials of other approaches did
  • Supplements and nutraceuticals: inflammation and other biomarkers 13 trials, no results posted yet
  • Mind-body and psychological approaches: mood, anxiety and wellbeing 4 trials, no results posted yet
Sources: ClinicalTrials.gov (trials, status, posted results); RepurpOS natural-product tiers (registry trials, PubMed, reference databases); OSMF biomarker atlas where available; OSMF non-drug evidence map (148 non-drug trials for this condition). Lists are shortened; the live pages carry every entry with its source: evidence-gap map · RepurpOS · condition page · biomarker atlas. Counts change daily. Nothing here is a recommendation to start, stop or change any treatment.